Divyaswathi Citla-Sridhar: Immune Risks Following Gene Therapy for Hemophilia A
Divyaswathi Citla-Sridhar, Associate Professor of Pediatrics and Associate Director at Arkansas Center for Bleeding Disorders, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Blood, adding:
“Pleased to share our publication in Blood on high-titer FVIII inhibitor formation in 2 patients following AAV gene therapy for hemophilia A.
This highlights a critical lesson: prior FVIII exposure does not guarantee immune tolerance to bioengineered FVIII transgenes.
As gene therapy advances, careful assessment of transgene immunogenicity remains essential.”
Title: Cases of High-Titer Inhibitor Formation After AAV Gene Therapy for Hemophilia A
Authors: Shelley E Crary, Divyaswathi Citla-Sridhar, C D’Ann Pierce, Guy Young
Stay updated o all scientific advances with Hemostasis Today.
-
Oct 22, 2026, 11:03Frailty and Healthy Aging in People With Hemophilia – JTH
-
Oct 22, 2026, 10:01Matthew Hazell: AABB 2026 – Beyond the Antibody Screen in Complex Immunohematology Reference Testing
-
Oct 22, 2026, 09:54Dr. Geoffrey Barnes Highlights Blood Clot Risks Following NFL Star Jalen Hurts’ Diagnosis – ISTH
-
Oct 22, 2026, 09:45Louise St. Germain Bannon: Closing the Awareness Gap in Women’s Health and Blood Clot Risks
-
Oct 22, 2026, 09:37Raghavendra Rao: Where Does the Great Saphenous Vein Terminate? Test Your Anatomy Knowledge
-
Oct 22, 2026, 09:32Gashaw Arega Mekonnen: Expansion of Pediatric Hematology and Oncology Services in Ethiopia
-
Oct 22, 2026, 09:23World Thrombosis Day Walk on a Beautiful Morning in Auckland – THANZ
-
Oct 22, 2026, 06:43Giacomo Buso: Lifelong Carotid Risk vs. Late-Stage Trial Neutrality
-
Oct 22, 2026, 06:35Aastha Gupta: Navigating the Diagnostic Challenge of Restricted NK-Cell Repertoires in Flow Cytometry